Compare GHC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHC | FOLD |
|---|---|---|
| Founded | 1877 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.5B |
| IPO Year | 1994 | 2006 |
| Metric | GHC | FOLD |
|---|---|---|
| Price | $1,069.20 | $14.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | 14.1K | ★ 3.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 66.47 | N/A |
| Revenue | ★ $2,932,099,000.00 | N/A |
| Revenue This Year | $10.54 | $20.50 |
| Revenue Next Year | $4.02 | $18.59 |
| P/E Ratio | $15.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $875.60 | $5.66 |
| 52 Week High | $1,224.76 | $14.39 |
| Indicator | GHC | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 68.21 |
| Support Level | $1,019.78 | $14.21 |
| Resistance Level | $1,115.27 | N/A |
| Average True Range (ATR) | 30.00 | 0.02 |
| MACD | 3.15 | -0.02 |
| Stochastic Oscillator | 63.46 | 71.43 |
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.